NFKB1 and COVID-19: Therefore, EC-specific inhibition of NF-κB signaling would likely be necessary to provide therapeutic benefit in patients with viral pneumonia, e.g., COVID-19 and influenza, by maintaining endothelial COUP-TF2 expression and enabling earlier, more effective endothelial repair.